Contribute Try STAT+ Today

In a boost for AbbVie (ABBV), a U.S. International Trade Commission judge this week made an initial determination that sales of a competing version of its best-selling Botox treatment should be banned for 10 years.

The ruling came in response to a complaint filed last year by Allergan, which AbbVie has since acquired, that a pair of rival companies — Evolus (ELOS) and Daewoong Pharmaceuticals — allegedly stole trade secrets that were used to develop a new wrinkle-smoothing product. A final decision from the ITC, however, is not due until November.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.